Samsung Biologics said it has completed its acquisition of a manufacturing facility in Rockville, Maryland, adding 60,000 liters of production capacity.
The company said Tuesday it finalized the purchase of the biopharmaceutical plant from GlaxoSmithKline on March 31 (local time), about three months after signing the deal in December. The buyer was its U.S. subsidiary, Samsung Biologics America.
The Rockville site is a 60,000-liter drug substance (DS) plant made up of two manufacturing buildings. It has infrastructure to produce antibody drugs at various scales, from clinical-stage batches to commercial production.
With the acquisition, Samsung Biologics said its total production capacity increased to 845,000 liters from 785,000 liters.
The company said the deal strengthens its ability to serve customers in North America and creates a two-hub manufacturing system linking Songdo, South Korea, and Rockville, offering global clients stable and flexible production options.
Samsung Biologics said it will retain all of the roughly 500 local specialists at the site to ensure operational continuity. It plans to integrate the two production bases to maintain supply of existing products and step up efforts to win new orders.
“This acquisition is meaningful progress in expanding our global manufacturing footprint,” CEO John Rim said. “Together with the Rockville site’s skilled workforce, we will maintain operational continuity and continue a stable supply system.”
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.